Lantheus (NASDAQ:LNTH) Releases FY 2026 Earnings Guidance

Lantheus (NASDAQ:LNTH) updated its FY 2026 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of 5.000-5.250 for the period, compared to the consensus estimate of 5.160. The company issued revenue guidance of $1.4 billion-$1.5 billion, compared to the consensus revenue estimate of $1.5 billion.

Lantheus Stock Down 0.7%

LNTH stock opened at $74.91 on Friday. Lantheus has a 1-year low of $47.25 and a 1-year high of $111.29. The business’s 50 day simple moving average is $68.15 and its 200 day simple moving average is $60.14. The company has a current ratio of 2.67, a quick ratio of 2.49 and a debt-to-equity ratio of 0.51. The firm has a market capitalization of $4.97 billion, a PE ratio of 22.23 and a beta of -0.08.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings results on Thursday, February 26th. The medical equipment provider reported $1.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.17 by $0.50. Lantheus had a return on equity of 30.37% and a net margin of 15.15%.The business had revenue of $406.79 million during the quarter, compared to the consensus estimate of $367.03 million. During the same quarter last year, the firm posted $1.59 EPS. The company’s quarterly revenue was up 4.0% on a year-over-year basis. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. As a group, research analysts anticipate that Lantheus will post 6.01 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the stock. JonesTrading reaffirmed a “hold” rating on shares of Lantheus in a report on Friday. Citizens Jmp boosted their price objective on Lantheus from $73.00 to $78.00 and gave the stock a “market outperform” rating in a report on Tuesday. Weiss Ratings raised Lantheus from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Tuesday, January 6th. Truist Financial set a $89.00 target price on Lantheus in a research note on Friday. Finally, Mizuho boosted their price target on Lantheus from $72.00 to $85.00 and gave the company an “outperform” rating in a research note on Friday. Seven equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $82.17.

Key Headlines Impacting Lantheus

Here are the key news stories impacting Lantheus this week:

• Positive Sentiment: Q4 results: Lantheus reported $1.67 EPS vs. $1.17 expected and revenue of $406.8M vs. $367.0M expected (revenue +4% y/y), showing operational strength and margin improvement. MarketBeat Earnings Report
• Positive Sentiment: Mizuho raised its price target to $85 and set an “outperform” rating, signaling increased analyst conviction and implied upside from current levels. Benzinga
• Positive Sentiment: William Blair upgraded Lantheus from “market perform” to “outperform,” adding another positive analyst endorsement. Street Insider
• Positive Sentiment: Citizens Jmp raised its price target to $78, a modest endorsement that supports the view of upside among some sell‑side analysts. American Banking News
• Neutral Sentiment: JonesTrading reaffirmed a “hold” rating on LNTH, reflecting mixed views on near‑term catalysts. TickerReport
• Neutral Sentiment: Investor materials and transcripts are available (earnings call transcript and presentation), useful for digging into product trends, margin drivers and pipeline commentary. Yahoo Finance Transcript Seeking Alpha Deck
• Negative Sentiment: FY2026 guidance was mixed: EPS guidance of $5.00–$5.25 is roughly in line with consensus (5.16), but revenue guidance of $1.4B–$1.5B leaves room for a slight top‑line miss vs. expectations — a conservative revenue range that could weigh on near‑term sentiment. GlobeNewswire Press Release

Institutional Investors Weigh In On Lantheus

Institutional investors and hedge funds have recently bought and sold shares of the company. Smartleaf Asset Management LLC lifted its stake in shares of Lantheus by 63.3% in the 4th quarter. Smartleaf Asset Management LLC now owns 508 shares of the medical equipment provider’s stock valued at $34,000 after purchasing an additional 197 shares during the period. Vident Advisory LLC grew its stake in Lantheus by 0.5% in the fourth quarter. Vident Advisory LLC now owns 44,763 shares of the medical equipment provider’s stock worth $2,979,000 after purchasing an additional 230 shares during the period. Parallel Advisors LLC raised its holdings in Lantheus by 122.6% in the fourth quarter. Parallel Advisors LLC now owns 541 shares of the medical equipment provider’s stock worth $36,000 after purchasing an additional 298 shares in the last quarter. Orion Porfolio Solutions LLC boosted its holdings in shares of Lantheus by 3.9% during the 2nd quarter. Orion Porfolio Solutions LLC now owns 10,010 shares of the medical equipment provider’s stock valued at $819,000 after buying an additional 377 shares in the last quarter. Finally, Osterweis Capital Management Inc. purchased a new stake in shares of Lantheus in the 2nd quarter worth about $36,000. Institutional investors own 99.06% of the company’s stock.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.